Skip to main content

Market Overview

GenMark Diagnostics Files For Emergency Use Authorization For COVID-19 Test

GenMark Diagnostics Files For Emergency Use Authorization For COVID-19 Test

GenMark Diagnostics, Inc (NASDAQ: GNMK) shares are headed higher again following an update from the company regarding its COVID-19 diagnostics test.

The company said it has submitted an Emergency Use Authorization, or EUA, to the FDA for its ePlex SARS-CoV-2 Test. Once the EUA is granted, the test could be used by clinical labs for detecting COVID-19.

The company said initial Research Use Only, or RUO, tests were shipped last week to several key customers to validate the assay design using clinical samples.

"EUA submission in just over a week from the initial RUO shipments of our ePlex test is a critical step to enable our customers to rapidly detect and possibly prevent the spread of the COVID-19 virus," said Scott Mendel, interim CEO of GenMark.

Several diagnostics companies have jumped into the fray to develop or distribute tests to diagnose the virus. Tuesday, Aytu Bioscience Inc (NASDAQ: AYTU) skyrocketed close to 500% on a COVID-19 test distribution deal.

GenMark shares were trading higher by 7.3% to $5.10 at time of publication.

Related Links:

How Close Are Biotechs To Bringing A COVID-19 Treatment To Market?

NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment


Related Articles (GNMK)

View Comments and Join the Discussion!

Posted-In: Coronavirus Covid-19Biotech News Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at